Bolt Biotherapeutics Inc (BOLT)
0.793
-0.03
(-3.89%)
USD |
NASDAQ |
May 17, 16:00
0.80
+0.01
(+0.88%)
After-Hours: 20:00
Bolt Biotherapeutics Enterprise Value: -61.12M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | -61.12M |
| May 16, 2024 | -59.89M |
| May 15, 2024 | -59.70M |
| May 14, 2024 | -41.02M |
| May 13, 2024 | -40.64M |
| May 10, 2024 | -43.31M |
| May 09, 2024 | -48.65M |
| May 08, 2024 | -49.03M |
| May 07, 2024 | -50.17M |
| May 06, 2024 | -49.41M |
| May 03, 2024 | -49.41M |
| May 02, 2024 | -49.41M |
| May 01, 2024 | -48.65M |
| April 30, 2024 | -49.22M |
| April 29, 2024 | -48.65M |
| April 26, 2024 | -49.03M |
| April 25, 2024 | -47.12M |
| April 24, 2024 | -45.59M |
| April 23, 2024 | -49.03M |
| April 22, 2024 | -49.03M |
| April 19, 2024 | -49.03M |
| April 18, 2024 | -47.88M |
| April 17, 2024 | -49.03M |
| April 16, 2024 | -47.50M |
| April 15, 2024 | -48.27M |
| Date | Value |
|---|---|
| April 12, 2024 | -45.60M |
| April 11, 2024 | -42.93M |
| April 10, 2024 | -43.69M |
| April 09, 2024 | -42.36M |
| April 08, 2024 | -39.12M |
| April 05, 2024 | -40.64M |
| April 04, 2024 | -40.64M |
| April 03, 2024 | -39.88M |
| April 02, 2024 | -37.97M |
| April 01, 2024 | -34.16M |
| March 31, 2024 | -37.97M |
| March 28, 2024 | -48.81M |
| March 27, 2024 | -55.67M |
| March 26, 2024 | -56.82M |
| March 25, 2024 | -56.44M |
| March 22, 2024 | -56.44M |
| March 21, 2024 | -57.96M |
| March 20, 2024 | -57.96M |
| March 19, 2024 | -58.34M |
| March 18, 2024 | -58.72M |
| March 15, 2024 | -59.87M |
| March 14, 2024 | -60.25M |
| March 13, 2024 | -58.15M |
| March 12, 2024 | -54.35M |
| March 11, 2024 | -53.97M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-138.07M
Minimum
May 06 2022
1.427B
Maximum
Mar 17 2021
57.80M
Average
-71.38M
Median
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 5.156M |
| Palatin Technologies Inc | 22.26M |
| iBio Inc | 16.77M |
| Theriva Biologics Inc | -8.901M |
| Oragenics Inc | 8.862M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.81M |
| Revenue (Quarterly) | 5.274M |
| Total Expenses (Quarterly) | 22.37M |
| EPS Diluted (Quarterly) | -0.28 |
| Profit Margin (Quarterly) | -205.0% |
| Earnings Yield | -209.4% |
| Normalized Earnings Yield | -209.36 |